| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2814 | Jcp678 | Novel irriversable serine hydrolases inhibitor |
|
| DCC2815 | jd-5006 | Peripheral Selective CB1 Receptor Antagonist |
|
| DCC2816 | Jesridonin | Novel apoptosis inducer, significantly inhibiting tumor growth in the xenograft model |
|
| DCC2817 | Jfd00950 | Novel human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1 |
|
| DCC2818 | Jg2-38 | Novel inhibitor of the heat shock protein 70 (Hsp70) with anti-proliferative activity in breast and prostate cancer cells |
|
| DCC2819 | Jh-i-17 | Novel type I Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4 |
|
| DCC2820 | Jh-i-25 | Novel Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4 |
|
| DCC2821 | Jk-136 | Novel Ras homologous A (RHOA) inhibitor, potently inhibiting cell viability and migration/invasion of gastric cancer (GC) cell lines, and mouse xenografts, diversely expressing RHOA, binding affinity for RHOA was >140-fold greater than Rhosin, a nonclinic |
|
| DCC2822 | Jk-31 (vegfr2/cdk1 Inhibitor) | Novel specific dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1), targeting cell cycle progression and angiogenesis |
|
| DCC2823 | Jlj-334 | Potent non-nucleoside inhibitor of HIV-1 reverse transcriptase (NNRTIs) |
|
| DCC2824 | Jmv2951 | Novel potent GHS-R1a agonist (EC50 (Ca ): 1.6 nM), significantly stimulating GH secretion |
|
| DCC2825 | Jmv3168 | Novel ghrelin receptor (GHS-R1a) antagonist [IC 50 (affinity): 5 nM IC 50 (Ca ): 60 nM] |
|
| DCC2826 | Jmv4484 | Novel partial inverse agonist of GHS-R1a (K i = 3 nM, EC 50 = 70 nM, Emax = −37%) |
|
| DCC2827 | Jmx0207 | Novel inhibitor of viral protease function, suppressing Zika virus Infection both In vitro and In vivo |
|
| DCC2828 | Jmx0254 | Novel Potent NS4B Inhibitor for the Treatment of Dengue Virus Infection |
|
| DCC2829 | Jmx0510-2 | Novel Potent Human Adenovirus Inhibitor, showing improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreasing cytotoxicity (CC50 = 156.8 μM), and lowering in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosam |
|
| DCC2830 | Jnj-1013 | Novel potent and selective IRAK1 degrader, effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells |
|
| DCC2831 | Jnj-10311795 | Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase |
|
| DCC2832 | Jnj-17029259 | Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor |
|
| DCC2833 | Jnj-17148066 | Estrogen receptor ESR1 agonist |
|
| DCC2834 | Jnj-1930942 | Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor |
|
| DCC2835 | Jnj-20788560 | Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent |
|
| DCC2836 | Jnj-26076713 | Novel EthR inhibitor, boosting antituberculous activity of ethionamide |
|
| DCC2837 | Jnj-28330835 | Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats |
|
| DCC2838 | Jnj-28583867 | Histamine H3 receptor antagonist and serotonin reuptake inhibitor |
|
| DCC2839 | Jnj-40068782 | Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors |
|
| DCC2840 | Jnj-40255293 | Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease |
|
| DCC2841 | Jnj-40264796 | Negative control for JNJ-40068782 |
|
| DCC2842 | JNJ-40355003 Featured | JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor. |
|
| DCC2843 | Jnj-40573663 | Negaive control for JNJ-42396302 |
|
